Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina develops DNA sequencing, array-based, informatics and proteomics technologies for research, clinical and applied markets. Company news commonly covers sequencing instruments and consumables, NovaSeq X demand, DRAGEN software releases, TruPath Genome analytical support, and applications in oncology, reproductive health, agriculture, rare disease and drug discovery.
Illumina updates also include collaborations around precision oncology testing, preventive and population genomics, pediatric cancer and rare disease data, and the Alliance for Genomic Discovery. Financial and corporate news covers revenue trends, operating margins, earnings guidance, share repurchase authorizations, acquisitions in multiomics and proteomics, and board or management changes.
Illumina (NASDAQ: ILMN) and NashBio announced expansion of the Alliance for Genomic Discovery on March 5, 2026: the core dataset grows to 312,000 whole genomes with longitudinal clinical data and a new multiomic initiative will add 50,000 whole genomes paired with proteomic data using Illumina Protein Prep.
Regeneron Genetics Center joins as the tenth member, and GSK is among the first participants in the proteomics expansion. Illumina's recent acquisition of SomaLogic proteomics technologies is cited as enabling the multiomic effort.
Illumina (NASDAQ: ILMN) announced on February 27, 2026 that Illumina Laboratory Services will provide clinical whole-genome sequencing and interpretation services to the Diagnostic Lab at the Florida Institute for Pediatric Rare Diseases (IPRD) at Florida State University College of Medicine. The collaboration aims to accelerate rare-disease diagnostics and shorten the diagnostic odyssey for patients.
The partnership builds on existing ties with FSU, used Illumina implementation support for workflow enablement, and coincides with Rare Disease Day events and a livestreamed talk by Illumina's chief medical officer.
Illumina (NASDAQ: ILMN) highlighted customer breakthroughs in oncology on Feb. 25, 2026, using spatial transcriptomics, 5-base sequencing, proteomics, and Illumina Connected Multiomics. Key claims include whole-transcriptome spatial datasets at 1 µm resolution, >2,000 unique transcripts per cell, and integrated methylation-aware cfDNA insights for harder-to-detect tumors.
Illumina (NASDAQ: ILMN) launched TruPath Genome on February 24, 2026, a whole‑genome solution claiming improved accuracy in difficult "dark" regions, megabase phasing up to 98%, a simplified ~10‑minute hands‑on workflow producing 16 genomes/day, and a listed consumables+analysis price of $395.
Data presented at AGBT and academic pilots report resolution of complex structural variants and single‑sample phasing for rare disease research.
Illumina (NASDAQ: ILMN) unveiled an 18-month roadmap of NovaSeq X updates delivering higher accuracy, throughput, speed, and flexibility.
Key metrics: Q70 quality introduction, output up to 35 billion reads (from 25B), 30% faster WGS runs (14B in 20–22 hours), new flow cells, staggered starts, and DRAGEN software improvements across ~8,901 systems.
Illumina (NASDAQ: ILMN) will webcast a management fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 12:10pm PT (3:10pm ET).
Investors can view the live webcast via the Events & Presentations section of the company's investor website; a replay will be archived for at least 30 days.
Illumina (Nasdaq: ILMN) reported Q4 2025 revenue of $1.16B (+5% year-over-year; ex-China $1.10B, +8%). Q4 GAAP diluted EPS was $2.16 (non-GAAP $1.35); FY 2025 revenue was $4.34B (flat) and FY GAAP diluted EPS was $5.45 (non-GAAP $4.84).
Key items: completed the SomaLogic acquisition, launched the Billion Cell Atlas, appointed Eric Green as CMO, achieved MOFCOM export-ban lift for sequencers while remaining on Chinas Unreliable Entities List. FY2026 guidance: revenue $4.5B –$4.6B; non-GAAP EPS $5.05 –$5.20.
Illumina (NASDAQ: ILMN) announced a sequencing agreement with the San Diego Zoo Wildlife Alliance to sequence up to 4,000 samples representing 1,300 species from the Frozen Zoo®, a 50-year-old biodiversity biobank. A subset will receive multiomic analysis, with whole-genome data made available to SDZWA and collaborators to support conservation research.
Illumina (NASDAQ: ILMN) completed its acquisition of SomaLogic on Jan. 30, 2026, expanding Illumina's multiomics and proteomics capabilities by combining SomaScan with Illumina's NGS ecosystem, DRAGEN software, and Connected Multiomics.
The transaction consideration was $350 million in cash at closing plus up to $75 million in near-term performance-based milestones and royalties; the deal was funded with cash on hand. Illumina will discuss financial implications on its Feb. 5, 2026 earnings call.
Illumina (NASDAQ: ILMN) announced that CMS will reimburse its FDA-approved TruSight™ Oncology Comprehensive (TSO Comprehensive) test at $2,989.55 per test under PLA code 0543U, effective January 1, 2026. The decision places TSO Comprehensive on the Clinical Laboratory Fee Schedule and establishes a predictable reimbursement pathway for Medicare beneficiaries. Illumina says broader reimbursement will enable more labs to provide in-house comprehensive genomic profiling (CGP) and expand access to precision oncology across hospitals, networks, and regional labs. Illumina also noted clinical markets drove growth, with ~60% of sequencing consumables revenue from clinical customers in 2025.